Visual outcome following treatment with aflibercept in patients with neovascular age-related macular degeneration

PurposeObjective: To evaluate the visual outcome, number of injections and causes for discontinuation of treatment with aflibercept in patients with neovascular age-related macular degeneration (nAMD).MethodsDesign: Retrospective chart review.Participants: The study included 350 eyes in 350 patients who initiated first time intravitreal therapy for nAMD in 2013–14.Descriptive statistical analysis of change in best-corrected visual acuity (BCVA) from presentation to 3 and 12 months after the first injection.ResultsThe patients’ mean age and visual acuity at baseline were stable at 80 years and 0.24 Snellen. Visual acuity increased significant with a mean of 6 injections; at 3 months to 0.38 Snellen, by 1 year to 0.41 Snellen for patients still in treatment; and to 0.35 Snellen for all patients with last observation carried forward.By 1 year 77% of eyes were still in treatment, 10% had discontinued treatment with no apparent activity of disease and only a mean of 3.3 injections; 10% had discontinued treatment due to low visual acuity, 3% were lost to follw-upConclusionTreatment with aflibecept in patients with nAMD showed excellent visual outcome for the majority of eyes treated.